Improving Early Detection and Treatment of Liver Cancer
Why This Matters
GlobalData is a leading data analytics and consulting company relied upon by major healthcare and pharmaceutical companies for strategic decision-making. Their analysis positions Helio's diagnostic technology alongside emerging immunotherapy regimens as a synergistic advance in liver cancer care.
Article Summary
Originally published by Pharmaceutical Technology (a GlobalData brand), this analysis examines how Helio's blood-based multi-analyte approach detects tumor-associated epigenetic signals in circulating cell-free DNA alongside protein biomarkers — enabling earlier identification of cancer even where conventional imaging is inconclusive. The article reports SEER data showing five-year survival drops from 37% (localized) to 3% (distant), and positions the Quest partnership alongside Phase III perioperative immunotherapy trials (IMbrave050, CARES-009), arguing that improved diagnostics could expand the population eligible for curative interventions. Available via Yahoo! News syndication.